Details of the Drug
General Information of Drug (ID: DMV4ICS)
Drug Name |
5-p-Tolylsulfanyl-quinazoline-2,4-diamine
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-(4-Tolylthio)-2,4-diaminoquinazoline; 168910-32-5; 5-[(4-METHYLPHENYL)SULFANYL]-2,4-QUINAZOLINEDIAMINE; CHEMBL83547; 5-[(4-methylphenyl)sulfanyl]quinazoline-2,4-diamine; TQ4; Maybridge3_004364; AC1L9JD9; Oprea1_160965; SCHEMBL2126685; BDBM18046; CTK0E5148; DTXSID80332215; MolPort-002-910-071; HMS1443G08; GW578; ZINC172633; HMS3604M19; CCG-44692; AKOS027447345; MCULE-8600056307; DB04306; IDI1_015751; 5-(p-Tolylthio)quinazoline-2,4-diamine; RT-010103; 5-(p-tolylsulfanyl)quinazoline-2,4-diamine; FT-0675290
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 282.4 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 3.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References